We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Veracyte Inc (VCYT) USD0.001

Sell:$37.00 Buy:$40.09 Change: $0.67 (1.72%)
NASDAQ:0.16%
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$37.00
Buy:$40.09
Change: $0.67 (1.72%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Sell:$37.00
Buy:$40.09
Change: $0.67 (1.72%)
Market closed |  Prices as at close on 22 November 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and assure patients. The Company offers tests for thyroid cancer (Afirma), prostate cancer (Decipher Prostate), breast cancer (Prosigna), interstitial lung diseases (Envisia), and bladder cancer (Decipher Bladder). Its Percepta Nasal Swab test is being run in its Clinical Laboratory Improvement Amendments (CLIA) lab in support of clinical studies and its tests for kidney cancer and lymphoma are in development, the latter as a companion diagnostic. Its products consist of the Prosigna breast cancer assay, the nCounter Analysis System, related diagnostic kits, and services. In the United States, it offers laboratory developed tests (LDTs), through its CLIA labs in South San Francisco and San Diego, California, supported by its cytopathology know-how in Austin, Texas. The Company also offers whole-genome MRD platform that enable it in early cancer diagnosis and risk assessment.

Contact details

Address:
6000 Shoreline Court, Suite 300
SOUTH SAN FRANCISCO
94080
United States
Telephone:
+1 (650) 2436300
Website:
https://www.veracyte.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
VCYT
ISIN:
US92337F1075
Market cap:
$3.04 billion
Shares in issue:
77.50 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Marc Stapley
    Chief Executive Officer, Director
  • Rebecca Chambers
    Chief Financial Officer
  • Annie Mcguire
    Chief Human Resource Officer, General Counsel
  • Phillip Febbo
    Chief Scientific Officer, Chief Medical Officer
  • John Leite
    Chief Commercial Officer - CLIA

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.